GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Gross Profit

Oryzon Genomics (STU:ORN) Gross Profit : €10.25 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Gross Profit?

Oryzon Genomics's gross profit for the three months ended in Mar. 2024 was €0.00 Mil. Oryzon Genomics's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €10.25 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Oryzon Genomics's gross profit for the three months ended in Mar. 2024 was €0.00 Mil. Oryzon Genomics's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Oryzon Genomics's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Oryzon Genomics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 10 years, the highest Gross Margin % of Oryzon Genomics was 24123.53%. The lowest was 115.81%. And the median was 395.67%.


Oryzon Genomics Gross Profit Historical Data

The historical data trend for Oryzon Genomics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Gross Profit Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.93 9.09 9.89 15.42 14.14

Oryzon Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 3.38 3.19 3.69 -

Competitive Comparison of Oryzon Genomics's Gross Profit

For the Biotechnology subindustry, Oryzon Genomics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Gross Profit falls into.



Oryzon Genomics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Oryzon Genomics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - -14.138
=14.14

Oryzon Genomics's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.25 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Oryzon Genomics's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Oryzon Genomics  (STU:ORN) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Oryzon Genomics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Oryzon Genomics Gross Profit Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Oryzon Genomics (STU:ORN) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.